Therapeutics/Diagnostics News

VANCOUVER, British Columbia — In a Healio video exclusive, Jan Wehkamp, MD, PhD, discusses results from the QUASAR study, in which Tremfya outperformed placebo in clinical response at weeks 12 and 24 among patients with ulcerative colitis.

VANCOUVER, British Columbia — Tirzepatide 15 mg was associated with the highest degree of weight loss compared with other glucagon-like peptide-1 agonists and placebo, according to a presenter at the ACG Annual Scientific Meeting.

VANCOUVER, British Columbia — In this Healio video, Paul Feuerstadt, MD, FACG, AGAF, discusses data that link health-related quality of life and microbiome composition among patients with recurrent Clostridioides difficile infection.

Treatment with apraglutide resulted in a 52% reduction in weekly parenteral support volume at 1 year among nine patients with short bowel syndrome with intestinal failure and colon-in-continuity, according to data presented at UEG week.

An app-based digital therapeutic was “largely effective” in reducing symptoms and improving quality of life, work productivity and health literacy among patients with irritable bowel syndrome, according to late-breaking data from UEG Week.

Skyrizi demonstrated non-inferiority to Stelara in clinical remission at 24 weeks, as well as superiority in endoscopic remission at 48 weeks, in patients with moderate to severe Crohn’s disease, according to data presented at UEG Week.

In a Healio video exclusive, Jan Wehkamp, MD, PhD, reports that treatment with Tremfya maintained clinical remission and endoscopic response through 3 years among patients with moderate to severe Crohn’s disease.

PRA023, an investigational antibody directed against tumor necrosis factor-like cytokine 1A, induced clinical remission at 12 weeks in significantly more patients with ulcerative colitis vs. placebo, according to data presented at UEG Week.

From the early days of homemade “poop shakes” blended in a backroom 15 years ago to the current world of FDA-approved live biotherapeutic products, it feels like we are at an inflection point with fecal microbiota transplantation.

Clostridioides difficile infection presents a unique treatment paradox for clinicians: Antibiotics are often both its cause and its cure.